Zhao Jingxiao, Wang Ping, Jiang Minmin, Yan Shuxun
First Clinical Medical College, Henan University of Chinese Medicine, Zhengzhou 450000.
Department of Endocrinology, First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou 450000, China.
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2023 Nov 28;48(11):1753-1759. doi: 10.11817/j.issn.1672-7347.2023.230187.
Thyroid-associated ophthalmopathy (TAO) is a multifactorial-mediated autoimmune orbital disease with the highest incidence of orbital disease in adults. Due to the complex clinical manifestations and prolonged course,TAO seriously affect the physical and mental health of patients.The pathogenesis of TAO has not been fully elucidated and the treatment lacks specificity. Therefore, in-depth research on the pathogenesis of TAO is to find effective treatments. In recent years, studies have suggested that there is gut microbiota disorder in TAO, and the risk factors of TAO can promote gut microbiota disorder. Disordered gut microbiota can participate in the occurrence and development of TAO via influencing T cell differentiation, mimicking autoantigens, and influencing host non-coding RNA expression. Modulating the gut microbiota also has therapeutic effects on TAO and is a promising therapeutic approach.
甲状腺相关眼病(TAO)是一种多因素介导的自身免疫性眼眶疾病,在成人眼眶疾病中发病率最高。由于临床表现复杂且病程迁延,TAO严重影响患者的身心健康。TAO的发病机制尚未完全阐明,治疗缺乏特异性。因此,深入研究TAO的发病机制以寻找有效的治疗方法。近年来,研究表明TAO存在肠道微生物群紊乱,且TAO的危险因素可促进肠道微生物群紊乱。紊乱的肠道微生物群可通过影响T细胞分化、模拟自身抗原以及影响宿主非编码RNA表达来参与TAO的发生和发展。调节肠道微生物群对TAO也有治疗作用,是一种有前景的治疗方法。